Financial Performance - The company's revenue for Q1 2025 was CNY 502,005,677.53, representing a 7.16% increase compared to CNY 468,475,325.62 in the same period last year[3] - Net profit attributable to shareholders was CNY 33,875,583.34, up 24.02% from CNY 27,315,351.75 year-over-year[3] - The basic earnings per share rose to CNY 0.08, a 14.29% increase from CNY 0.07 in the prior year[3] - Operating profit for Q1 2025 was RMB 38,979,110.09, compared to RMB 33,132,260.39 in Q1 2024, indicating a growth of 17.4%[14] - The net profit for Q1 2025 was CNY 36,069,339.72, an increase of 25.5% compared to CNY 28,754,862.43 in Q1 2024[15] - The total comprehensive income for Q1 2025 reached CNY 44,809,854.58, up 87.8% from CNY 23,842,215.83 in Q1 2024[15] - Basic and diluted earnings per share for Q1 2025 were both CNY 0.08, compared to CNY 0.07 in Q1 2024, reflecting a 14.3% increase[16] Research and Development - R&D expenses totaled CNY 29,464,412.16, an increase of 33.72% from CNY 22,034,279.90 in the previous year, accounting for 5.87% of revenue[4] - Research and development expenses for Q1 2025 were RMB 28,466,477.75, up from RMB 21,378,735.83 in Q1 2024, indicating a year-over-year increase of 33.0%[14] - Research and development expenses increased significantly to CNY 23,150,884.01 in Q1 2025, compared to CNY 14,955,959.11 in Q1 2024, marking a rise of 54.56%[22] Cash Flow and Liquidity - The net cash flow from operating activities was negative at CNY -147,278,064.55, compared to CNY -108,479,469.28 in the same period last year[3] - Cash inflow from operating activities in Q1 2025 was CNY 442,719,320.52, compared to CNY 401,224,877.38 in Q1 2024, marking a growth of 10.3%[17] - The net cash flow from investing activities for Q1 2025 was CNY 200,057,471.63, a significant recovery from a negative CNY 57,580,146.82 in Q1 2024[18] - The company reported a net cash outflow from financing activities of CNY 3,821,247.76 in Q1 2025, compared to a larger outflow of CNY 51,717,442.10 in Q1 2024[18] - The cash and cash equivalents increased from CNY 67,496,386.38 to CNY 163,367,400.01, showing a growth of 142.43%[20] - The ending balance of cash and cash equivalents was $67,396,386.38 in Q1 2025, down from $249,121,587.45 in Q1 2024[26] Assets and Liabilities - The total assets at the end of the reporting period were CNY 3,637,738,270.37, a slight increase of 0.02% from CNY 3,636,977,990.07 at the end of the previous year[4] - Total liabilities decreased to RMB 1,079,854,783.92 as of March 31, 2025, from RMB 1,123,904,358.20 at the end of 2024, a reduction of 3.9%[12] - Shareholders' equity increased to RMB 2,557,883,486.45 as of March 31, 2025, compared to RMB 2,513,073,631.87 at the end of 2024, marking a growth of 1.8%[12] - The company's total assets increased from CNY 2,658,057,108.36 to CNY 2,771,614,940.75, reflecting a growth of approximately 4.26%[21] - The company's total liabilities rose from CNY 498,681,691.01 to CNY 626,535,556.98, indicating an increase of approximately 25.66%[21] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 9,593[7] - The largest shareholder, Li Ruiqiang, holds 51.61% of the shares, totaling 214,810,148 shares[7]

Financial Performance - Novogene reported a revenue of RMB 1.2 billion for the last fiscal year, representing a year-over-year growth of 25%[19]. - The company's operating revenue for 2024 reached ¥2,111,319,193.13, representing a year-on-year increase of 5.45% compared to ¥2,002,107,701.39 in 2023[27]. - Net profit attributable to shareholders for 2024 was ¥196,788,496.06, up 10.52% from ¥178,059,764.27 in 2023, driven by increased operating revenue[30]. - The basic and diluted earnings per share for 2024 were both ¥0.48, reflecting a 9.09% increase from ¥0.44 in 2023[29]. - The company's cash flow from operating activities for 2024 was ¥385,538,071.76, a 15.36% increase from ¥334,197,677.56 in 2023[27]. - The total assets at the end of 2024 were ¥3,636,977,990.07, a 1.18% increase from ¥3,594,420,954.11 at the end of 2023[28]. - The net assets attributable to shareholders increased to ¥2,489,835,892.67, up 1.32% from ¥2,457,457,998.48 in 2023[28]. - The company's R&D expenditure as a percentage of operating revenue was 6.38% in 2024, up from 6.20% in 2023[29]. - The net profit after deducting non-recurring gains and losses for 2024 was ¥170,759,798.53, a 21.98% increase from ¥139,987,341.83 in 2023[30]. Dividend and Share Capital - The company plans to distribute a cash dividend of RMB 0.05 per share (including tax), totaling approximately RMB 20,252,926.60, which represents 10.29% of the net profit attributable to shareholders in the consolidated financial statements for 2024[7]. - As of December 31, 2024, the total share capital of the company is 416,200,000 shares, after deducting 11,141,468 shares held in the repurchase special securities account[7]. - The company does not plan to issue bonus shares or convert capital reserves into share capital for the 2024 fiscal year[7]. Audit and Compliance - The company has received a standard unqualified audit report from Lixin Certified Public Accountants[6]. - The company's board of directors and supervisory board members have ensured the accuracy and completeness of the annual report[3]. - The company has not reported any instances where more than half of the directors could not guarantee the authenticity of the annual report[10]. - The company has confirmed that there are no non-operating fund occupations by controlling shareholders or related parties[10]. - The company has not violated any decision-making procedures in providing guarantees[10]. Market and Growth Strategy - Novogene anticipates a revenue growth of 20% for the upcoming fiscal year, projecting revenues to reach RMB 1.44 billion[19]. - The company is investing RMB 200 million in R&D for new genomic technologies and products in the next year[19]. - Novogene plans to expand its market presence in Europe and North America, targeting a 30% increase in international sales[19]. - The company has successfully completed the acquisition of a smaller biotech firm, enhancing its capabilities in next-generation sequencing[19]. - The company is focusing on developing non-invasive prenatal testing solutions, which are expected to contribute significantly to future revenues[19]. Customer and Client Base - The company has expanded its user base to over 10,000 active clients, an increase of 15% compared to the previous year[19]. - Novogene's customer satisfaction rate has reached 90%, reflecting improvements in service delivery and product quality[19]. - The company serves nearly 7,300 clients globally, covering approximately 90 countries and regions, with a strong presence in North America, Europe, and Southeast Asia[50]. Research and Development - The company has developed a comprehensive multi-omics service system, including technologies for genomics, transcriptomics, and proteomics[43]. - The company is actively exploring clinical applications of long-read sequencing and methylation sequencing technologies[46]. - The company has published or been cited in over 30,467 SCI articles with a cumulative impact factor of 208,245.37 and holds 79 invention patents and 495 software copyrights as of December 31, 2024[49]. - The company has established collaborations with multiple top-tier hospitals for its pathogen metagenomics high-throughput detection products[47]. - The company has automated the library construction process and developed over a hundred personalized extraction methods for non-standard samples[57]. Technology and Innovation - The company has introduced multiple new sequencing systems, including Illumina's NovaSeq X Plus and PacBio's Revio, enhancing sequencing throughput and meeting the latest sequencing demands[80]. - The company is actively exploring AI technology applications, with its AI bioinformatics expert "Novi" already available for free to clients, providing standardized and efficient bioinformatics analysis solutions[81]. - The company has developed a unique competitive advantage in several advanced sequencing technologies, including de novo sequencing and single-cell sequencing[118]. - The company aims to enhance its product services and technology platforms, focusing on various business lines including livestock, animals, plants, crops, microorganisms, cancer, and single-cell research to better meet customer needs[182]. Risks and Challenges - The company faces risks related to a lack of clinical application qualifications and a single product line, which could impact its competitive edge if new products are not developed timely[120]. - The company is exposed to intense market competition, which may lead to significant price declines and affect overall profitability if operational strategies are not adjusted[123]. - The company relies heavily on a few suppliers for sequencing instruments and reagents, which poses a risk; it plans to diversify its supplier base to mitigate this dependency[124]. Corporate Governance - The company has improved its corporate governance structure in compliance with relevant laws and regulations, ensuring transparency and accountability in operations[191]. - The board of directors actively participates in meetings and committees, ensuring the protection of shareholders' rights and interests[192]. - The company has established a fair and transparent performance evaluation system to attract and retain talent, promoting sustainable human resource development[189].

诺禾致源公告，2024年营业收入21.11亿元，同比增长5.45%。归属于上市公司股东的净利润1.97亿元， 同比增长10.52%。公司拟向全体股东每股派发现金红利0.05元(含税)，合计拟派发现金红利人民币 2025.29万元(含税)。 ...

诺禾致源688315 时间: 2025年4月14日星期一 38.99分综合得分 偏弱 趋势方向 主力成本分析 13.91 元 当日主力成本 13.55 元 5日主力成本 1次 14.94 元 20日主力成本 15.33 元 60日主力成本 周期内涨跌停 过去一年内该股 涨停 跌停 0 次 北向资金数据 | 持股量122.39万股 | 占流通比0.29% | | --- | --- | | 昨日净买入6.66万股 | 昨日增仓比0.016% | | 5日增仓比-0.167% | 20日增仓比-0.076% | 技术面分析 13.93 短期压力位 12.35 短期支撑位 17.25 中期压力位 中期支撑位 目前短线趋势不慎明朗，静待主力资金选择方向； 目前中期趋势不慎明朗，静待主力资金选择方向 K线形态 ★好友反攻★ 底部反转 资金流数据 2025年04月14日的资金流向数据方面 | 主力资金净流入40.08万元 | | --- | | 占总成交额1% | | 超大单净流入262.54万元 | | 大单净流出222.46万元 | | 散户资金净流出134.31万 | 关联行业/概念板块 医疗服务 1.51%、医疗 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：688315 证券简称：诺禾致源 公告编号：2025-009 北京诺禾致源科技股份有限公司 关于会计估计变更的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ● 根据《企业会计准则第28号一一会计政策、会计估计变更和差错更正》的相关规定，北京诺禾致源科 技股份有限公司（以下简称"公司"）本次会计估计变更采用未来适用法进行相应的处理，无需对公司已 披露的财务报表进行追溯调整，对以往各年度财务状况和经营成果不会产生影响。 ● 本次会计估计变更自2025年1月1日起开始执行。 一、本次固定资产残值率会计估计变更情况概述 （一）会计估计变更原因 公司作为基因测序行业中游服务商，其测序主要生产设备的残值率原按行业惯例设定为5%。近年来， 随着国产测序设备技术突破及海外厂商加速布局，上游设备供给显著增加，服役期满的设备处置价格持 续下行。这一结构性变化使得设备处置时的实际残值率与会计估计残值率产生偏离。 根据公司近五年设备全周期运营数据，测序主要生产设备 ...

立信会计师事务所(特殊普通合伙) BDO ? BDO CHINA SHU LUN PAN CERTIFIED PUBLIC ACCOUNTANTS LLP 关于北京诺禾致源科技股份有限公司 2025 年度 会计估计变更情况专项说明的专项报告 信会师报字[2025]第 ZG11188 号 北京诺禾致源科技股份有限公司全体股东; 我们接受委托,审核了后附的北京诺禾致源科技股份有限公司 (以下简称"诺禾致源")《关于北京诺禾致源科技股份有限公司 2025 年度会计估计变更事项专项说明》(以下简称"专项说明")。就本次 拟实施的固定资产中的测序主要生产设备残值率变更事项,诺禾致源 管理层根据《科创板上市公司自律监管指南第 3 号 -- 日常信息披 露》等相关规定编制了后附的专项说明,以供诺禾致源按照相关规定 披露会计估计变更事项之目的参考使用。 诺禾致源管理层的责任是编制专项说明,并保证其内容真实、准 确、完整,不存在虚假记载、误导性陈述或重大遗漏。我们的责任是 在实施审核程序的基础上对专项说明提出审核结论。我们的审核是参 照《中国注册会计师审计准则第 1321 号 -- 审计会计估计(包括公 允价值会计估计）和相关 ...

中信证券股份有限公司 关于北京诺禾致源科技股份有限公司 开展外汇套期保值业务的核查意见 中信证券股份有限公司（以下简称"中信证券"）作为北京诺禾致源科技股 份有限公司（以下简称"诺禾致源"、"公司"）的保荐机构，根据《证券发行上市 保荐业务管理办法》《上海证券交易所股票上市规则》《上海证券交易所科创板股 票上市规则》及《上海证券交易所上市公司自律监管指引第 11 号——持续督导》 等有关法律法规及规范性文件的规定，对诺禾致源开展外汇套期保值业务的事项 进行了了认真、审慎的核查，核查情况如下： 一、开展外汇套期保值业务的必要性 公司境外业务主要采用美元等外币进行结算，因此当汇率出现较大波动时， 汇兑损益将对公司的经营业绩造成一定影响。为有效规避外汇市场的风险，防范 汇率波动对公司经营业绩造成不利影响，提高外汇资金使用效率，合理降低财务 费用，公司拟开展外汇套期保值业务。公司的外汇套期保值业务以正常生产经营 为基础，以规避和防范汇率风险为目的，不进行单纯以盈利为目的的投机和套利 交易。 二、拟开展的套期保值业务概述 公司目前境外收入占比较大，为有效规避外汇市场风险，防范汇率大幅波动 对公司经营业绩造成的不利影响， ...

中信证券股份有限公司 关于北京诺禾致源科技股份有限公司 使用暂时闲置募集资金进行现金管理的核查意见 中信证券股份有限公司（以下简称"中信证券"或"保荐机构"）作为北京 诺禾致源科技股份有限公司（以下简称"诺禾致源"或"公司"）首次公开发行 并在科创板上市及 2022 年向特定对象发行股票的持续督导保荐机构，根据《证 券发行上市保荐业务管理办法》、《上市公司监管指引第 2 号——上市公司募集资 金管理和使用的监管要求（2022 年修订）》、《上海证券交易所科创板上市公司自 律监管指引第 1 号——规范运作》、《上海证券交易所科创板股票上市规则》，对 诺禾致源使用暂时闲置募集资金进行现金管理的事项进行了审慎核查，核查情况 如下： 一、募集资金的基本情况 （一）2021 年首次公开发行股票实际募集资金情况 经中国证券监督管理委员会《关于同意北京诺禾致源科技股份有限公司首次 公开发行股票注册的批复》（证监许可〔2021〕737 号）同意，并经上海证券交 易所同意，公司首次公开发行人民币普通股（A 股）4,020 万股，募集资金总额 为人民币 512,952,000.00 元，扣除发行费用人民币 63,182,374. ...

证券代码：688315 证券简称：诺禾致源 公告编号：2025-009 北京诺禾致源科技股份有限公司 关于会计估计变更的公告 2025 年 4 月 11 日，公司召开第三届董事会审计委员会第十三次会议，审议 通过了《关于会计估计变更的议案》，召开第三届董事会第二十一次会议、第三 届监事会第十九次会议，审议通过了《关于会计估计变更的议案》。 1 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 根据《企业会计准则第 28 号——会计政策、会计估计变更和差错更正》 的相关规定，北京诺禾致源科技股份有限公司（以下简称"公司"）本次会计估 计变更采用未来适用法进行相应的处理，无需对公司已披露的财务报表进行追溯 调整，对以往各年度财务状况和经营成果不会产生影响。 本次会计估计变更自 2025 年 1 月 1 日起开始执行。 一、本次固定资产残值率会计估计变更情况概述 （一） 会计估计变更原因 公司作为基因测序行业中游服务商，其测序主要生产设备的残值率原按行业 惯例设定为 5%。近年来，随着国产测序设备技术突破及海外厂商 ...

证券代码：688315 证券简称： 诺禾致源 公告编号：2025-010 北京诺禾致源科技股份有限公司 关于使用暂时闲置募集资金进行现金管理的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 北京诺禾致源科技股份有限公司（以下简称"公司"）于 2025 年 4 月 11 日 召开第三届董事会第二十一次会议、第三届监事会第十九次会议，审议通过了《关 于使用暂时闲置募集资金进行现金管理的议案》，同意公司拟使用不超过人民币 3,610.00 万元（含本数）的暂时闲置募集资金进行现金管理，用于购买安全性高、 流动性好的投资产品（包括但不限于结构性存款、协定存款、通知存款、定期存 款、大额存单、收益凭证等其他理财产品），使用期限自公司第三届董事会第二 十一次会议决议之日起 12 个月之内有效。在上述额度和决议有效期内，资金可 以滚动使用。公司董事会授权财务总监行使该项决策并签署相关法律文件，包括 但不限于选择合格的理财产品发行主体、明确理财金额、选择理财产品品种、签 署合同等。保荐机构中信证券股份有限公司对本事项出具了明确的核查 ...